Regulation - Pricing, Eisai

Filter

Current filters:

PricingEisai

Popular Filters

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

12-05-2014

Japanese drug major Eisai has exercised its option to jointly develop and commercialize its clinical…

Biogen IdecEisaiFycompaGermanyItalyLicensingNeurologicalPharmaceuticalPricingRegulationZebinix

Eisai temporarily suspend Fycompa in Germany, following negative G-BA decision

25-06-2013

Japanese drug major Eisai (TYO: 4523) said today (June 25) that, "with regret," it will suspend temporarily…

EisaiEuropeFycompaMarkets & MarketingNeurologicalPharmaceuticalPricingRegulation

Eisai disagrees with Germany's IQWiG report on epilepsy drug Fycompa

19-12-2012

In the assessment report by the German Institute for Quality and Efficiency in Health Care (IQWiG) on…

EisaiEuropeFycompaNeurologicalPharmaceuticalPricingRegulation

Scottish Medicines Consortium approves Eisai's Fycompa and Novartis' Lucentis for DME

11-12-2012

Japanese drug major Eisai's (TYO: 4523) Fycompa (perampanel), a treatment for partial epilepsy, is now…

EisaiEuropeFycompaLucentisNeurologicalNovartisPharmaceuticalPricingRegulation

Eisai breast cancer drug still viewed as not cost effective by NICE

03-04-2012

In a third rejection, the UK drug watchdog the National Institute for Health and clinical Excellence…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

Added benefit of Eisai’s Halaven not proven, says Germany’s IQWiG

17-02-2012

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

UK’s NICE rejects Eisai’s Halaven for advanced breast cancer

17-11-2011

In a second negative from the UK’s National Institute for Health and Clinical Excellence, in final…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

Parexel

Parexel

Back to top